{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T21:32:22Z","timestamp":1775943142817,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00134-017-5036-1","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T15:18:10Z","timestamp":1514560690000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM\/ESCMID\/WAAAR round table on multi-drug resistance"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1017-9748","authenticated-orcid":false,"given":"Jan J.","family":"De Waele","sequence":"first","affiliation":[]},{"given":"Murat","family":"Akova","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Antonelli","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Canton","sequence":"additional","affiliation":[]},{"given":"Jean","family":"Carlet","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"De Backer","sequence":"additional","affiliation":[]},{"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Garnacho-Montero","sequence":"additional","affiliation":[]},{"given":"Jozef","family":"Kesecioglu","sequence":"additional","affiliation":[]},{"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[]},{"given":"Mervyn","family":"Mer","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"additional","affiliation":[]},{"given":"Mario","family":"Poljak","sequence":"additional","affiliation":[]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[]},{"given":"Jesus","family":"Rodriguez Bano","sequence":"additional","affiliation":[]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[]},{"given":"Jean-Ralph","family":"Zahar","sequence":"additional","affiliation":[]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"5036_CR1","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","volume":"38","author":"A Tabah","year":"2012","unstructured":"Tabah A, Koulenti D, Laupland K, Misset B, Valles J, de Bruzzi Carvalho F, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF (2012) Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 38:1930\u20131945","journal-title":"Intensive Care Med"},{"key":"5036_CR2","unstructured":"O\u2019Neill J (2014) Antimicrobial resistance: tackling a crisis for the health  and wealth of nations. Rev Antimicrob Resist 1\u201316"},{"key":"5036_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s00134-017-4878-x","volume":"43","author":"M Bassetti","year":"2017","unstructured":"Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A (2017) Antimicrobial resistance in the next 30\u00a0years, humankind, bugs and drugs: a visionary approach. Intensive Care Med 43:1464\u20131475","journal-title":"Intensive Care Med"},{"key":"5036_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00134-015-3719-z","volume":"41","author":"M Bassetti","year":"2015","unstructured":"Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar JR, Poulakou G (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776\u2013795","journal-title":"Intensive Care Med"},{"key":"5036_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MCC.0000000000000124","volume":"20","author":"I Mart\u00edn-Loeches","year":"2014","unstructured":"Mart\u00edn-Loeches I, Diaz E, Vall\u00e9s J (2014) Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care 20:516\u2013524","journal-title":"Curr Opin Crit Care"},{"key":"5036_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ajic.2015.09.006","volume":"44","author":"BM Miller","year":"2016","unstructured":"Miller BM, Johnson SW (2016) Demographic and infection characteristics of patients with carbapenem-resistant Enterobacteriaceae in a community hospital: development of a bedside clinical score for risk assessment. Am J Infect Control 44:134\u2013137","journal-title":"Am J Infect Control"},{"key":"5036_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14787210.2017.1251840","volume":"15","author":"M Bassetti","year":"2017","unstructured":"Bassetti M, Carnelutti A, Peghin M (2017) Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti-infect Ther 15:55\u201365","journal-title":"Expert Rev Anti-infect Ther"},{"key":"5036_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3343\/alm.2013.33.1.14","volume":"33","author":"A van Belkum","year":"2013","unstructured":"van Belkum A, Durand G, Peyret M, Chatellier S, Zambardi G, Schrenzel J, Shortridge D, Engelhardt A, Dunne WM (2013) Rapid clinical bacteriology and its future impact. Ann Lab Med 33:14\u201327","journal-title":"Ann Lab Med"},{"key":"5036_CR9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/jac\/dkv423","volume":"71","author":"F Barbier","year":"2016","unstructured":"Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S, Dumenil AS, Lemiale V, Mourvillier B, Clec\u2019h C, Darmon M, Laurent V, Marcotte G, Lucet JC, Souweine B, Zahar JR, Timsit JF, Outcomerea SG (2016) Colonization and infection with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure. J Antimicrob Chemother 71:1088\u20131097","journal-title":"J Antimicrob Chemother"},{"key":"5036_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/QCO.0000000000000251","volume":"29","author":"M Bassetti","year":"2016","unstructured":"Bassetti M, Righi E, Carnelutti A (2016) New therapeutic options for respiratory tract infections. Curr Opin Infect Dis 29:178\u2013186","journal-title":"Curr Opin Infect Dis"},{"key":"5036_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s00134-017-4789-x","volume":"43","author":"JA Roberts","year":"2017","unstructured":"Roberts JA, Lefrant JY, Lipman J (2017) What\u2019s new in pharmacokinetics of antimicrobials in AKI and RRT. Intensive Care Med 43:904\u2013906","journal-title":"Intensive Care Med"},{"key":"5036_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00134-017-4780-6","volume":"43","author":"T T\u00e4ngd\u00e9n","year":"2017","unstructured":"T\u00e4ngd\u00e9n T, Ramos Mart\u00edn V, Felton TW, Nielsen EI, Marchand S, Br\u00fcggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA, Infection Section for the European Society of Intensive Care Medicine TPAPSGOTESOCMAID, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases (2017) The role of infection models and PK\/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med 43:1021\u20131032","journal-title":"Intensive Care Med"},{"key":"5036_CR13","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/jac\/dkv165","volume":"70","author":"A Tabah","year":"2015","unstructured":"Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, Timsit JF, Roberts JA, Working Group for Antimicrobial Use in the ICU within the Infection Section of the European Society of Intensive Care Medicine ESICM (2015) The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 70:2671\u20132677","journal-title":"J Antimicrob Chemother"},{"key":"5036_CR14","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1378\/chest.13-0076","volume":"144","author":"G Dimopoulos","year":"2013","unstructured":"Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK (2013) Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 144:1759\u20131767","journal-title":"Chest"},{"key":"5036_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s00134-012-2563-7","volume":"38","author":"DK Matthaiou","year":"2012","unstructured":"Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G (2012) An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 38:940\u2013949","journal-title":"Intensive Care Med"},{"key":"5036_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E de Jong","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16:819\u2013827","journal-title":"Lancet Infect Dis"},{"key":"5036_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","volume":"387","author":"AH Holmes","year":"2016","unstructured":"Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ (2016) Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 387:176\u2013187","journal-title":"Lancet"},{"key":"5036_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1473-3099(13)70295-0","volume":"14","author":"LP Derde","year":"2014","unstructured":"Derde LP, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJ, Gniadkowski M, Hryniewicz W, Empel J, Dautzenberg MJ, Annane D, Aragao I, Chalfine A, Dumpis U, Esteves F, Giamarellou H, Muzlovic I, Nardi G, Petrikkos GL, Tomic V, Marti AT, Stammet P, Brun-Buisson C, Bonten MJ (2014) Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 14:31\u201339","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 4","key":"5036_CR19","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/382690","volume":"38","author":"DL Paterson","year":"2004","unstructured":"Paterson DL (2004) Collateral damage\u201d from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38(Suppl 4):S341\u2013S345","journal-title":"Clin Infect Dis"},{"key":"5036_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.addr.2014.10.027","volume":"78","author":"BD Brooks","year":"2014","unstructured":"Brooks BD, Brooks AE (2014) Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev 78:14\u201327","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-017-5036-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-017-5036-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-017-5036-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:00:36Z","timestamp":1744174836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-017-5036-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,29]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["5036"],"URL":"https:\/\/doi.org\/10.1007\/s00134-017-5036-1","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,29]]},"assertion":[{"value":"11 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jan De Waele has consulted for Bayer Healthcare, Merck, and Pfizer. Murat Akova had received grants to support institutional research projects from Pfizer and MSD, and has participated accredited educational activities by Pfizer and Astellas. Massimo Antonelli received research grants from Orion, Toray, Pfizer and MSD, and received fees from GE, Maquet, Nihon Koden, Intersurgical and Orion for participation to International Boards. Rafael Canton has participated in educational programs sponsored by Angelini, AstraZeneca, Pfizer and MSD, and in research activities funded by AstraZeneca and MSD. Jean Carlet has participated in advisory boards with Beckton Dikinson, and has been a consultant for Cooper Alliance. George Dimopoulos has been a consultant for Bayer Healthcare, Merck, and Pfizer and Glenmark. Jos\u00e9 Garnacho-Montero has served as speaker for MSD, Astellas and has received research support from Astellas. Jozef Kesecioglu has received honorarium from Xenios AG. Jeff Lipman has consulted for Bayer and MSD. Mervyn Mer has participated in educational activities funded by MSD, Pfizer, Gilead, AstraZeneca, Sun Pharma. Jason Roberts has consulted for Astellas, bioMerieux and Bayer and has received investigator-initiated grant funding from MSD, Cardeas Pharma and The Medicines Company. Jesus Rodriguez-Bano has participated in research projects from AstraZeneca and InfectoPharm, and participated in accredited educational activities funded by Merck. Jean-Francois Timsit has participated in scientific boards of Bayer, Merck, Gilead, Paratek, Maat Pharma; the University Hospital of Jean-Francois Timsit received research grants from Merck, 3\u00a0M and Astellas and participated in advisory boards for 3\u00a0M, Merck, Gilead, Pfizer, Paratek, Bayer,. Jean-Ralph Zahar has consulted for Merck and Pfizer. The other authors state that they have no conflicts of interest. Matteo Bassetti has participated in advisory boards and\/or received speaker honoraria from Achaogen, Angelini, Astellas, AstraZeneca, Bayer, Basilea, Gilead, Menarini, MSD, Pfizer, The Medicine Company, Tetraphase and Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}